News

The pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16

The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.

Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.

U.S. stock futures rose while oil edged higher in early European trade as investors also await U.S. job openings data for the month of June.

Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures...

U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”

Stock Market Today: The Dow Jones index fell Monday, while tech futures rallied. Micron stock and Sandisk rebounded in premarket trading.

U.S. lawmakers have opened national security investigations into Merck's clinical trial activities in China. The probes focus on trials conducted in politically sensitive regions, including Xinjiang, and at hospitals linked to the Chinese military. Key concerns include intellectual property protection, ethical oversight, and the handling of sensitive biotechnology data. Merck, listed as NYSE:MRK, is a large global pharmaceutical company with a heavy focus on prescription medicines,...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of underperformance have turned drug stocks from a defensive holding into something more interesting for growth-heavy portfolios. “I think you just have to look ... Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.

FTSE 100 up 8 points to 10,341 Oil prices soften on Israel-Lebanon ceasefire CMC Markets nears five-year high on results 2.56pm: Toddlers' picnic on Wall Street As expected, Wall Street has opened like a toddlers' picnic, with everyone heading off in different...

The healthcare sector outperformed the rest of the market over the past week.

Futures fell as AI leaders Micron, Sandisk and more keep sliding. Home Depot beat views while Google I/O kicks off.

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash